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Whole brain radiotherapy (WBRT) for the palliation of metastases, or as prophylaxis to prevent intracranial metastases, can be
associated with subacute and late decline in memory and other cognitive functions. Moreover, these changes are often increased
in both frequency and severity when cranial irradiation is combined with the use of systemic or intrathecal chemotherapy.
Approaches to preventing or reducing this toxicity include the use of stereotactic radiosurgery (SRS) instead of WBRT; dose
reduction for PCI; exclusion of the limbic circuit, hippocampal formation, and/or neural stem cell regions of the brain during
radiotherapy; avoidance of intrathecal and/or systemic chemotherapy during radiotherapy; the use of high-dose, systemic
chemotherapy in lieu of WBRT. This review discusses these concepts in detail as well as providing both neuroanatomic and
radiobiologic background relevant to these issues.
1.Introduction
Whole brain radiation therapy (WBRT) is a mainstay of
therapy for the treatment of primary and metastatic tumors
involving the brain [1–3]. WBRT entails treatment of the
whole intracranial compartment (brain and brainstem)
down to the foramen magnum or to the bottom of either
the ﬁrst or second cervical vertebrae, with a uniform dose of
radiation, typically administered with opposed lateral ﬁelds
and blocks to protect the lenses. Multiple dose fractionation
regimens have been employed for WBRT, with no one
schedule having been conclusively proven better than others,
although single fraction therapy (ex. 10Gy in a single
fraction) has been shown to result in greater toxicity [4].
Common utilized treatment schedules include 2.5Gy ×
14 or 15 fractions, or 3Gy × 10 fractions. In the setting
of intracranial metastases, patients with RTOG RPA class
III (Table 1) disease are often managed with WBRT alone,
while patients with RPA class I or II disease are frequently
managed by a combination of modalities, including WBRT
alone, surgical resection followed by WBRT, stereotactic
radiosurgery (SRS) alone (particularly for Class I patients),
or SRS in combination with WBRT [5–9]. Unfortunately,
WBRT is associated with late brain toxicities, which range
in severity from mild deﬁcits in cognitive dysfunction to
overt dementia in up to 11% of patients depending on
the population studied, the length of follow up, and the
type of chemotherapy employed [10–13]. The sequelae of
treatment are even more severe in pediatric patients treated
with WBRT, in whom hearing loss, severe global cognitive
deﬁciencies, and neuro-endocrine deﬁcits may develop [14–
16]. In patients 60 years of age and older with primary
CNS lymphoma, the combination of WBRT and high-
dose methotrexate regimens has resulted in severe to fatal
leukoencephalopathy resulting in the frequent omission of
cranial radiotherapy in this context [17].
Prophylacticcranialirradiation (PCI)hasbecomeastan-
dard of care for selected patients with limited and extensive
stage small cell lung cancer (SCLC) who have shown beneﬁt
with systemic treatment. PCI has also been explored in the
context of nonsmall cell lung cancer (NSCLC), but in this2 Journal of Oncology
Table 1: RTOG RPA Classiﬁcation for brain metastases.
Class Characteristics Median Survival
(months)
I
KPS 70 or greater, age 65 years
or less, primary disease
controlled, no extracranial
metastases
7.1
II All others 4.2
III KPS < 70 2.3
context has not been shown to improve overall survival [18–
22]. A recent RTOG study (RTOG 0214) exploring the use of
PCI in NSCLC was presented at the 2009 ASTRO (American
SocietyforTherapeuticRadiologyandOncology)meetingin
Chicago, IL. [23, 24] 340 patients with Stage III nonsmall cell
lung cancer, who showed no evidence of tumor progression
after treatment of their primary tumor, were randomized to
be treated with PCI or undergo observation from 2002 to
2007. PCI resulted in a reduction in the incidence of brain
metastases from 18% to 8%, but did not impact overall
survival [24]. Importantly, while PCI did not signiﬁcantly
impact overall reported quality of life, it did result in lower
ratesofbothimmediateanddelayedrecall,suggestedthatthe
use of PCI impairs memory function in treated patients [24].
The concept underlying PCI is to eliminate microscopic
deposits of metastatic tumor within the brain and/or
brainstem before they become clinically manifest. Without
PCI, more than 60% of small cell lung cancer patients will
eventually develop clinically detectable and/or symptomatic
brain metastases at some point during the course of their
disease,andPCIreducesthisratetoapproximately20%[25].
The treatment ﬁeld for PCI is similar to WBRT in that the
whole brain and brainstem down to the foramen magnum
or the bottom of the ﬁrst or second cervical vertebrae is
treated to a uniform dose, with most patients being treated
using opposed laterals with lens blocks. Multiple treatment
schedules are employed, with no one schedule clearly
showing superiority to others [26] .Ar e c e n tp r o s p e c t i v e
study found that there was no signiﬁcant reduction in the
number of brain metastases for 36Gy in 18 fractions versus
25Gy in 10 fractions, while overall survival was worse for
unclear reasons in the higher dose arm [26]. The authors
concluded that 25Gy in 10 fractions should remain the
standard of care in this setting [26]. In the setting of both
limited and extensive stage small cell lung cancer, the use
of PCI has resulted in statistically signiﬁcant improvements
i no v e r a l ls u r v i v a l( O S )[ 27, 28]. As these patients are at
risk for cognitive deﬁcits from multiple causes such as age-
related cerebral atrophy, preexisting cerebrovascular disease,
anxiety,depression,andchemotherapyeﬀects,therehasbeen
controversy regarding the extent to which PCI contributes
to observed neurocognitive deﬁcits [29]. However, with
recent increases in mean overall survival and an increased
number of longer-term survivors, the contribution of PCI
to the development of neurocognitive deﬁcits is becoming
more clearly deﬁned [30]. Finally, PCI for pediatric patients
with high risk acute lymphocytic leukemia (ALL) is known
to cause signiﬁcant late sequelae and this knowledge has
promptedreductionsintheindicationsfor,anddosesof,PCI
in this context [30–34].
In this article we review these issues in further detail and
discuss the diﬀerent methods currently being employed and
explored in an eﬀort to reduce neurocognitive toxicity.
2. Toxicity of CranialIrradiation
The eﬀects of cranial irradiation may be roughly divided
into acute, subacute, and chronic [35]. Acute side eﬀects,
which occur during or within a few weeks of radiation
therapy, include fatigue, alopecia, nausea, and eﬀects related
to exacerbation of baseline cerebral edema such as headache,
nausea, focal deﬁcits, and when severe changes in mental
status. Subacute symptoms (those occurring after the com-
pletion of radiotherapy but within three months of the end
of treatment) are relatively rare and limited primarily to
the somnolence syndrome and, less frequently, early onset
leukoencephalopathy. The pathophysiology of the somno-
lence syndrome is probably related to transient demyeli-
nation of cerebral white matter (analogous to Lhermitte’s
syndrome after spinal irradiation). Leukoencephalopathy,
on the other hand, is believed to represent a more severe
manifestation of demyelination and may be fatal. These
white matter changes may be more prominent in older
patients with vascular risk factors, and evidence of this
damage can be identiﬁed before other gross changes are
evident on MRI by early changes in fractional anisotropy
(FA) as identiﬁed on diﬀusion tensor imaging (DTI) after
the delivery of PCI [36]. Similar changes in FA on DTI can
be seen in pediatric patients who have been treated with
radiotherapy for medulloblastoma, with one recent study
showing a mean reduction in FA of 16.5% in treated patients
versus controls [37]. These reductions in FA were found
to correlate with a younger age at the time of treatment
a n dd e c l i n e si ns c h o o lp e r f o r m a n c e[ 37]. Late side eﬀects,
which occur six months or later after radiation therapy,
include overt radionecrosis of the brain (with areas of
focal coagulative necrosis) and progressive microvascular
or vascular occlusion with a subsequent increased risk of
stroke. Rarely this may mimic Moyamoya syndrome as seen
in other contexts not involving radiotherapy or malignancy
[38–41].
Various systems have been developed to describe these
eﬀects, including (among others) the NCI Common Toxicity
Criteria Version 2.0 (available at http://ctep.cancer.gov)
and the RTOG/EORTC LENT-SOMA systems [42]. These
scoring systems’ deﬁnitions of neurotoxicity are shown in
Tables 2 and 3. However, more subtle deﬁcits in cognitive
function are not accounted for in these systems, nor are all
of the neuroendocrinologic sequelae of therapy.
Late toxicities in the brain are highly feared sequelae of
cranial irradiation in both adults and children because they
are highly debilitating and irreversible. The axonal tracts
that connect the cerebral cortex to the subcortical gangliae,
spinal cord, and brain stem nuclei do so in series, such that
damage to any part of the sequence adversely aﬀects [43].Journal of Oncology 3
Table 2: RTOG/EORTC Late Morbidity Scoring System for Brain.
Grade 0 None
Grade 1 Mild headache, slight
lethargy
Grade 2 Moderate headache, great
lethargy
Grade 3
Severe headache, severe
CNS dysfunction (partial
loss of power or dyskinesia)
Grade 4 Seizure, paralysis, coma
Grade 5 Death
The generally accepted TD5/5 and TD50/5 (radiation doses
which, when delivered to a given type of tissue in a typical
patient population, will result in a 5% or 50% rate of Grade
3 or higher toxicity at a time point 5 years removed from
the radiation exposure, resp.) after treating the whole brain
withstandardfractionationare45Gyand60Gy,respectively,
and for partial brain radiation exposure are 60Gy and 75Gy
[44]. Due to the slow rate of cell turnover for neuronal and
glial elements, the brain represents a late responding tissue,
with an accepted α/β ratio of about 2Gy [45]. This suggests
that treatment of the brain with smaller daily or fractional
radiation doses might reduce risk of late sequelae. However,
the use of smaller radiation fractions also necessitates the
deliveryofahighertotaldoseofradiationtoachievethesame
degree of tumor control [43].
Various treatment schedules have been developed for the
administration of WBRT in the setting of brain metastases
[46] .O n ec o m m o n l yu t i l i z e ds c h e d u l ei s3 0 G yi n1 0
fractions, which (assuming an alpha/beta ratio of 2Gy
for late neurologic sequelae) correlates with a biologically
equivalent dose (BED) of 75Gy2, theoretically below the
TD5/5 of whole brain (45Gy by standard fractionation at
2Gy per fraction, which corresponds to a BED of 100Gy2).
Other commonly used schedules include 2.5Gy × 14 or
15 fractions, which result in BED values of 78.75Gy2 and
84.4Gy2, respectively, again below the accepted TD5/5 for
whole brain radiation exposure. Thus, all of these treatment
schedules should result in rates of late neurologic sequelae
that are signiﬁcantly less than 5%. However, the NCI and
EORTC/RTOG toxicity scoring systems (Tables 2-3)d on o t
include the readily clinically identiﬁed changes in cognition
and behavior that are well documented after these therapies
[10–16].
T h em o s tf r e q u e n t l yd e s c r i b e da d v e r s ee ﬀects in adults
treated with WBRT include problems with the consolidation
of new memory, poor attention span/concentration, visual-
spatial diﬃculties, diﬃculty with executive planning, and
poor ﬁne motor control [10]. A recently published study
by Welzel et al. prospectively assessed cognitive function
in patients being treated with either WBRT (40Gy in 20
fractions or PCI (36Gy in 18 fractions) at baseline, after 1–
3 fractions, after the last fraction, and at 6–8 weeks after
the completion of radiation therapy [13]. These authors
found that acute declines in verbal memory were seen with
WBRT (but not PCI) patients after 1–3 fractions and at
the completion of treatment, while subacute declines in
verbal memory were seen in both WBRT and PCI patients
6–8 weeks after the completion of treatment [13]. On
multivariate analysis, they found that these deﬁcits persisted
evenafteraccountingfortheuseofchemotherapy,KPSscore,
and the presence of depression and/or anxiety. They found
no signiﬁcant declines in visual memory or attention span
[13].
In some cases, late neurological deﬁcits can be severe
enough to cause overt dementia, wherein the patient’s global
level of functioning is severely impaired and the patient is
not aware of these changes. This is in contrast to more subtle
cognitive deﬁcits that are commonly seen and of which the
patient is typically well aware. The incidence of dementia
after cranial irradiation has been reported to be as high as
11% in patients with long-term followup [11], and these
long-term sequelae have been shown to correlate with and
precede decline in patient-reported quality of life (QOL),
[12, 13].
PCI has variably been described as having no eﬀect on
cognitive function, adversely aﬀecting cognitive function,
and even initially improving cognitive function in adult
patients [13, 47–51]. As reported by Welzel et al., PCI
patients appear to start out with lower baseline cognitive
functioning scores than the WBRT patients, have a transient
improvement in simple reaction time (the ability to respond
t oa na c u t es t i m u l u s )d u r i n ga n da tt h ee n do fr a d i a t i o n
therapy, and subsequently have a decline in verbal memory
6–8 weeks after completing therapy [13]. A report recently
released by the EORTC of patient-reported quality of life
scores after PCI showed a signiﬁcant decline in QOL up
to 3 months after the completion of treatment, although
the most frequently reported complaints were for alopecia
and fatigue and the global QOL scores were less adversely
aﬀected [30]. For individual patients demonstrating brain
metastases following PCI, it can be diﬃcult to determine
the relative contribution of the recurrence and the PCI when
neurocognitive decline is identiﬁed [52]. Tumor progression
may particularly contribute to declines in cognitive function
in patients with signiﬁcant peritumoral edema [53]. Finally,
small cell lung cancer may, even in the absence of overt
intracranial metastatic involvement, adversely aﬀect cogni-
tive function by mechanisms that are not clearly understood,
possibly paraneoplastic [54].
Exposureofcerebralvasculature,particularlysmallarter-
ies and arterioles, is known to cause the late development
of hyaline-type arteriosclerosis with a subsequent increased
risk of ischemic stroke [38]. In very young children with
signiﬁcant exposures to the anterior Circle of Willis region,
changes can be seen which include bilateral carotid occlusion
with the subsequent development of transdural anastamoses
and a “net” or “cloud” of small collateral vessels; these
changes collectively are known as moyamoya syndrome [38–
41]. The moyamoya changes seen after cranial irradiation
are essentially identical to those seen in primary moyamoya
(Nishimoto’s disease) and result in similar clinical manifes-
tations such as cerebral ischemic strokes, recurrent transient
ischemic attacks (TIAs), motor deﬁcits, sensory deﬁcits,4 Journal of Oncology
Table 3: NCI Common Toxicity Criteria Version 2.0 Summary.
Grade 0 Normal
Grade 1
Confusion/disorientation which resolves without sequelae, somnolence/dizziness/extrapyramidal
symptoms/insomnia/memory loss/mood alterations/neuropathy/personality changes/pyramidal
symptoms/tremor/vertigo not interfering with daily function, mild atrophy or limited T2 hyperintensities on
MRI (<1/3 of cerebrum), nystagmus
Grade 2
Persistent confusion/disorientation/poor attention span not interfering with daily function,
somnolence/dizziness/extrapyramidal symptoms/insomnia/memory loss/mood
alterations/neuropathy/personality changes/pyramidal symptoms/tremor/vertigo/cranial neuropathies not
interfering with activities of daily living (ADL), moderate atrophy or more extensive T2 hyperintensities on
MRI (1/3-2/3 of cerebrum) extending into centrum ovale, nystagmus
Grade 3
Delusions, hallucinations, syncope, severe atrophy or near total T2 hyperintensities on MRI +/− focal white
matter necrosis, persistent confusion/disorientation/poor attention span/somnolence/dizziness/extrapyramidal
symptoms/insomnia/memory loss/mood alterations/neuropathy/personality changes/pyramidal
symptoms/tremor/vertigo/cranial neuropathies interfering with activities of daily living (ADL)
Grade 4 Bedridden/disabled due to brain toxicity, requiring hospitalization doe to risk to self/others, psychotic, unable
to communicate, amnesia, diﬀuse calciﬁcation or necrosis, paralysis
Grade 5 Death
global cognitive dysfunction, convulsions, and/or migraine-
like headaches [38].
The signiﬁcant late sequelae associated with cranial RT
have stimulated interest in ﬁnding ways to avoid this toxicity
without sacriﬁcing clinical outcomes for this eﬀective and
widely available therapy.
3. WBRT and PCIinthe PediatricPopulation
WBRT is a standard part of the treatment approach for
primaryCNSpediatrictumorsthathaveapropensityfordis-
semination along the neuraxis, including anaplastic ependy-
moma, medulloblastoma, ependymoblastoma, pineoblas-
toma, atypical rhabdoid/teratoid tumor, nonseminomatous
germ cell tumor, and choroid plexus tumors. WBRT in this
setting may or may not be combined with spinal irradiation,
and the doses used vary depending upon the tumor type, the
ageofthepatient,andtheclinicalcontext[55–59].Anumber
of approaches have been used to minimize the late toxicity of
cranial irradiation for these patients.
For standard risk medulloblastoma, the dose of cranial
spinal irradiation (CSI) (including the WBRT dose) has been
reducedfrom36Gyto23.4Gyinaneﬀort to reduce some
of the late eﬀects of cranial irradiation [60]. For intracranial
germinomas either whole-ventricular radiation therapy or
chemotherapy followed by involved-ﬁeld radiation therapy
is now preferred over WBRT, again in an eﬀort to spare the
child the late sequelae of treatment [61, 62]. Chemotherapy
without radiation therapy has been utilized in very young
patients (3 years of age and less) as a primary therapy,
adjuvant therapy, or “bridge” therapy to delay the use of
radiation therapy for primary CNS tumors until patients
are older and better able to tolerate the eﬀects of cranial
irradiation [63, 64]. Chemotherapy alone or as adjuvant
therapy has also been used as a treatment modality for
intracranial germinomas and nongerminomatous germ cell
tumors, but with unacceptably high failure rates [65].
For pediatric patients with acute lymphoblastic leukemia
(ALL) and acute myelogenous leukemia (AML), WBRT is
utilized as an eﬀective therapy for patients who present with
overt CNS involvement and those who relapse in the CNS
[66–69]. However, given the known late eﬀects of cranial
irradiation in the pediatric population, a number of groups
and institutions have developed protocols which exclude
WBRT even in patients with overt CNS involvement or who
relapse in the brain after initial treatment [70–72].
PCI is currently employed as part of standard therapy
for 2–20% of patients with ALL who have no overt CNS
involvement but have a number of other high risk features
(age >9y e a r so l do r<1 year old, T cell phenotype, WBC
greater than 50,000 or 100,000, extramedullary disease,
presence of Philadelphia chromosome, and poor response to
induction therapy)[66,67].Thed o seo fPC Ihassy st e mi call y
beenreducedfrom24Gyto18Gy ,andsomeprotocolsnow
employ doses as low as 12Gy [73–75]. However, even at
a dose of 18Gy, there is evidence of late cognitive and
neuron-endocrinologicsequelaeinthesepatients,evenwhen
treatment is delivered on a hyperfractionated schedule of
0.9Gy twice daily [16, 70–74].
St. Jude Children’s Hospital has extensively studied the
cognitive and other late neurologic side eﬀects of cranial
irradiation in children [15, 34, 76–78]. In one study, they
found that the patient’s age and the percent volume of
supratentorial brain irradiated to varying dose levels (0–
20Gy, 20–40Gy, 40–65Gy) correlated with IQ level after
cranial irradiation, with younger age at the time of treatment
andthetreatmentoflargerpercentvolumesofsupratentorial
brain to higher doses correlating signiﬁcantly with declines
in IQ after treatment [76]. In another study evaluating the
feasibility of ﬁeld reduction after resection of infratento-
rial ependymomas, they tested neurocognitive function at
baseline and at varying time points after cranial radiation
and found that patients treated with ﬁelds encompassing the
tumor bed/tumor and 1cm margin (as opposed to a typical
larger ﬁeld) had no detectable neurocognitive deﬁcits afterJournal of Oncology 5
treatment, suggesting that sparing the cochlea (to preserve
hearing) and avoiding irradiation of the supratentorial brain
minimizedtheriskoflateneurocognitivesequelae[77].After
partitioning the brain into 5 compartments (total brain,
supratentorial brain, infratentorial brain, right temporal
lobe, and left temporal lobe), they found that irradiation of
the supratentorial compartment and temporal lobes resulted
in signiﬁcant declines in IQ regardless of dose level, with
each Gy of exposure having a similar impact on declines in
IQ [34]. The cognitive deﬁcits seen after cranial irradiation
seem to be due to an inability to develop new skills and to
process new information, rather than a loss of previously
acquired skills and information [15]. The factors that seem
to correlate most strongly with cognitive decline after cranial
irradiation are a younger age at the time of treatment,
longer time interval since treatment, female sex, presence
of hydrocephalus, higher volume of supratentorial brain
irradiated, and higher radiation dose to the supratentorial
brain [78].
Hearing loss also contributes to the learning diﬃculties
these pediatric patients face after cranial irradiation, and can
result from irradiation of the cochlea/inner ear and/or the
use of ototoxic drugs such as platinum agents [75]. One of
the goals of ﬁeld reduction in the treatment of infratentorial
pediatric brain tumors is to minimize cochlear irradiation.
For example, in the context of craniospinal irradiation for
the treatment of medulloblastoma, the boost ﬁeld has been
systematicallyreducedfromtreatmentofthewholeposterior
fossa, to treatment of the tumor resection bed with a 2cm
margin, to recent eﬀorts at treating the tumor resection bed
with even smaller margins [14, 75, 79–81]. IMRT and proton
therapy have also been utilized in the treatment of pediatric
CNStumorswiththegoalofreducingcochleardoseanddose
to the brainstem and other critical local structures [82–85].
Thus, in the pediatric population, approaches to reduc-
ing the late neurotoxicity, endocrinopathies, and ototoxicity
associated with cranial irradiation have included avoidance
of cranial irradiation altogether, dose reduction, ﬁeld size
reduction, use of IMRT, and use of proton therapy. The
growing trend in recent trials, as exempliﬁed by the recently
published Total Therapy XV study from St. Jude Children’s
hospital, has been to avoid cranial irradiation altogether
through the use of risk-adapted intrathecal and systemic
chemotherapy regimens [86].
4. Omission of WBRT in Primary
CNS Lymphoma
The treatment of primary CNS lymphoma has evolved
over the years, with earlier trials utilizing whole brain
radiation therapy (WBRT) alone, and subsequent trials
using induction chemotherapy followed by WBRT (with
or without more chemotherapy after radiation therapy), or
chemotherapy alone [17, 87–101]. RTOG 83-15 was a phase
II trial which treated patients with WBRT to a dose of 40Gy
in 20 fractions, followed by a sequential boost to the patient’s
gross disease of 20Gy in 10 fractions [87]. This trial resulted
in a median OS of only 12.2 months and a 2-year OS of
28% [87]. Schultz et al., in a subsequent phase I/II trial
(RTOG 88-06), treated patients with 2 cycles of induction
CHOD (cyclophosphamide, doxorubicin, vincristine, and
dexamethasone) followed by WBRT to a dose of 41.4Gy in
23fractionsandasequentialconedownboosttothepatient’s
gross disease of 18Gy in 10 fractions (total 59.4Gy) [90].
This trial produced a median OS of 16.1 months and a 2-
year OS of 42%, slightly better than the results found in 83-
15, but on direct comparison the diﬀerence was not found
to be statistically signiﬁcant, and the authors concluded that
induction chemotherapy did not improve survival versus
radiotherapy alone [87, 88]. Of note, both 83-15 and 88-
06 found that OS was signiﬁcantly improved in patients less
than 60 years old [87, 88].
DeAngelis et al. in RTOG 93-10 treated patients with ﬁve
cycles of methotrexate-based chemotherapy (IV methotrex-
ate 2.5g/m2, vincristine, procarbazine, and IT methotrexate
12g), followed by WBRT to a dose of 45Gy in 25 fractions
and then high dose cytarabine as consolidation therapy [91].
They found a median OS of 36.9 months and a median
progression-free survival (PFS) of 24 months, signiﬁcantly
better than the results seen in 83-15 and 88-06 [91]. As in the
two prior trials, this trial found that patients younger than
age 60 had a signiﬁcantly better median OS (50.4 months)
than patients aged 60 years or older (21.8 months) [91].
Unfortunately, they also found that 15% of the patients
(12 total patients) experienced severe delayed neurotoxicity,
particularly diﬀuse leukoencephalopathy [91]. 8 of these 12
patients died as a result of their leukoencephalopathy [91].
The trial was amended to allow a lower dose of hyper-
fractionated WBRT (36Gy in 30 fractions, two fractions per
day)givenover3weeksforpatientswithacompleteresponse
(CR) to induction chemotherapy, in an eﬀort to reduce the
morbidity of treatment without compromising outcomes
[92]. Unfortunately, neurocognitive outcomes as assessed
by minimental status examination (MMSE) showed no
signiﬁcant improvement with this hyperfractionated WBRT
versus standard fractionated WBRT, with 10% of the hyper-
fractionated patients experiencing grade 5 neurotoxicity by 4
years after treatment [92]. Also, hyperfractionation did not
improve OS or PFS [92].
InvestigatorsatMSKCC(MemorialSloan-KetteringCan-
cer Center) have published a retrospective review of 185
patients treated with high-dose chemotherapy and WBRT
and found a 24% rate of signiﬁcant neurotoxicity by 5 years
after the completion of treatment [98]. In a separate report,
the same group reported on a series of 5 patients (median
age 74 years old) who died of treatment-induced diﬀuse
leukoencephalopathy and found that signiﬁcant clinical
s i g n so fn e u r o t o x i c i t yc o u l db ei d e n t i ﬁ e da se a r l ya s1
month after the completion of therapy, suggesting that this
potentially lethal consequence of treatment is not always a
delayed phenomenon, but one which could be seen very
early in some patients [99]. The rate of signiﬁcant late
neurotoxicity with combined modality therapy seems to be
age related, with patients aged 60 years and older having
rates of anywhere from 10% to 83% in various reports
[17, 88–93]. These patients are known to have a poorer
outcome than younger patients independent of the use of6 Journal of Oncology
combined modality therapy and subsequent neurotoxicity,
and age greater than 60 years old is considered a poor
prognostic factor using scoring systems from MSKCC and
the International Extranodal Lymphoma Study Group [100,
101]. Delayed neurotoxicity is the leading cause of morbidity
after treatment and is often fatal [17, 98, 99]. Because of this
high rate of toxicity, a number of groups have begun treating
primary CNS lymphoma patients with chemotherapy alone,
reserving radiotherapy for treatment failures [17, 97, 100,
101]. These studies have variably reported high rates of
failure in younger patients (especially less than 60 years old)
in some series, but survival rates in older patients are similar
or superior to the results seen with combined modality
therapy [17, 94–97]. This has led some investigators to
concludethatcombinedmodalitytherapyshouldbereserved
for patients younger than age 60, while in older patients it
should be reserved for salvage [17, 94, 96].
Thus, because of the high risk of delayed neurotoxicity
after combined modality therapy for primary CNS lym-
phoma, particularly in the elderly, WBRT is increasingly
being used as salvage therapy alone rather than as a
component of initial therapy despite its proven eﬃcacy [17,
91, 98, 99].
5. SRS as Monotherapy for Brain Metastases
Stereotactic radiosurgery (SRS) is a technique by which a
single large fraction of ionizing radiation is delivered with
submillimeter accuracy to a small treatment volume, most of
which is tumor. Initially restricted to patients with a solitary
brain metastasis, SRS has now been applied in the setting of
multiple brain metastases, and as a single modality [102–
113]. Because of the steep dose gradients achieved using
SRS, it has been proposed as a means by which to minimize
the radiation dose to normal brain, hopefully translating
into an improvement in cognitive sparing. Many authors
have reported local control and survival outcomes after
using SRS with or without WBRT [8, 9, 102, 104, 108–
110, 112, 113]. WBRT consistently improves local control
and decreases distant intracranial failures, but the addition
of WBRT has had an inconsistent impact on survival [8, 9,
102, 104, 107–113]. Still, it has been increasingly noted that
the outcomes of survival and local control do not adequately
describe the relevant outcomes in the brain metastases
population; neurocognitive function (NCF) and quality of
life (QOL), which has been shown to be tightly linked to
NCF, are also critical endpoints which may be linked to
factors other than the use of radiotherapy, such as control of
progression within the CNS, use of chemotherapy, or use of
antiepileptic medications [102, 103, 114–118]. In particular,
some studies have found that progression of disease within
the CNS is a stronger predictor of poor QOL and NCF
than the toxicity of therapy, including radiotherapy, and that
control of CNS disease may actually improve these outcomes
[114].
Chang et al. recently published the results of a ran-
domized controlled trial in which patients with 1–3 brain
metastases were treated with SRS alone or combined with
a course of WBRT (37.5Gy in 15 fractions of 2.5Gy each)
[113]. The primary endpoint of this study was neurocog-
nitive function as assessed by the HVLT-R (Hopkins Verbal
LearningTest-Revised)at4monthsfollowingthecompletion
of therapy; secondary endpoints included control within the
CNS and overall survival [113]. The trial was stopped after
58 patients had been enrolled due to early stopping rules
because of a signiﬁcant decline in memory function at 4
months following therapy in the SRS + WBRT arm of the
study; no signiﬁcant diﬀerence was noted in overall survival
at 4 months, but the rate of intracranial failure was higher at
1 year in the SRS alone arm (73% for SRS alone versus 27%
f o rS R S+W B R T)[ 113]. The authors of this study concluded
that patients with 1–3 brain metastases should be managed
initially with SRS alone followed by close observation [113].
Longitudinal data tracking the NCF of patients receiving
WBRT, SRS, or both are sparse. Chang et al. prospectively
assessed 15 patients with 1–3 metastases receiving treatment
with SRS alone [103]. A comprehensive battery of tests
evaluating neurocognitive function (NCF) was performed
on each patient evaluating attention, memory, dexterity,
and executive function. 67% of patients were found to
have a deﬁcit in at least one domain prior to treatment.
In accordance with the data of others, patients with larger
tumor volume (>3cm 3) were found to have worse NCF.
ImmediatelyfollowingSRS,allpatientsexperiencedadecline
in at least one domain, but in the 5 patients who underwent
long-term followup, 80% demonstrated stable/improved
learning memory and 60% had stable/improved executive
function and dexterity [103].
Kondziolka et al. compared the morbidity of SRS and
WBRT from the patient’s perspective via a retrospective
survey in 200 consecutive patients [112]. Patients whose
treatment included WBRT felt they had signiﬁcantly more
problemswithfatigue,short-termmemory,long-termmem-
ory, concentration, depression, and fatigue. Overall, SRS was
thought to be a good treatment by 76% of patients, whereas
only 56% of patients thought WBRT was a good treatment
[112].
Aoyama et al. performed prospective NCF assessment
within the context of a phase III trial randomizing 132
patientsbetweenSRS+WBRTandSRSalone[102,104].The
MMSE (Mini-Mental Status exam) was used as a surrogate
for NCF and was obtained prior to treatment, 1 month after
treatment, and every three months thereafter if possible.
92 patients were available for follow-up MMSE, of these,
39 were abnormal (<27) at baseline. Of these 39 patients,
20 (51%) experienced an improvement in MMSE after
treatment, 9 in the SRS group, and 11 in the combined
modality group. Actuarial preservation of MMSE score ≥27
at12,24,and36monthswas78.8%,78.8%,and22.5%inthe
SRS + WBRT group, versus 53.3%, 42.6%, and 42.6% in the
SRS alone group. Deterioration was attributed to RT toxicity
in 5 patients in the SRS + WBRT group, while no patients
receivingSRSalonehadatoxicevent.Intracranialrecurrence
was deemed the cause of NCF decline in 3 and 11 patients
in the WBRT + SRS and SRS alone groups, respectively
[102]. The data of Aoyama et al., while subject to limitations,
suggests that the omission of WBRT decreases intracranialJournal of Oncology 7
control and may negatively impact NCF over the ﬁrst 12–
24 months. Of concern, long-term survivors in the WBRT
+ SRS group appear to demonstrate a continued decline in
MMSE that may represent the late toxicity of WBRT, while
the long-term survivors receiving SRS alone display stable
MMSE[102].Theseresultsmustbeinterpretedwithcaution,
however, because of the small number of patients available
for followup at the late time points [102].
The utilization of SRS in the absence of WBRT does
not appear to be a perfect solution to the problem of
neurocognitive dysfunction in patients with intracranial
metastases because of the known increased rates of local
progression within the brain seen in patients treated with
SRS alone [102–106, 108–113]. Further understanding of
the complexities of neurocognitive toxicity will only be
achievedwhenthoroughNCFevaluationisastandardpartof
every investigation exploring therapies for brain metastases.
Now that the feasibility of large-scale NCF testing during
brain metastases trials has been demonstrated, the fund of
knowledgewillundoubtedlygrow,allowingtheoptimization
of the therapeutic index [118].
6.HippocampalSparing
Several groups have recently investigated the safety and
feasibility of sparing the hippocampus while simultaneously
treating the rest of the brain with radiotherapy [119–
121]. The hippocampus (Figure 1) occupies the ventro-
medial aspect of the temporal lobe, lying posterior to the
amygdaloid complex and lateral to the temporal horn of
the lateral ventricle [122]. Functionally, the hippocampus is
primarily involved in the consolidation of new memories. It
iscomposedofthedentategyrus,whichinadditiontoitsrole
in memory consolidation is also important in the achieving
and maintaining of “happy” states, and the cornu ammonis
(CA1–CA3 regions) [123]. A speciﬁc subregion within the
dentate gyrus is the subgranular zone (SGZ), which contains
neural stem cells (NSC) that are involved in the repair
of damage from various insults to the CNS (including
radiation therapy) [124]. These cells are also important in
maintaining the ability to learn throughout life. The axons
that arise from hippocampal neurons become the fornix, a
white matter tract that extends from the posterior aspect of
the hippocampal formation and around the third ventricle
(adjacent to the corpus callosum) to eventually synapse at
the mammillary bodies (part of the hypothalamus), which
are also involved in the consolidation of new memories
[123].
The hippocampus is rarely involved by intracranial
metastatic disease [118, 121]. Ghia et al. at the University of
Wisconsin recently reviewed the records of 272 intracranial
metastases and found that only 3.3% of lesions were within
5mm of the hippocampus, while 86.4% of lesions were
>15mm from the hippocampus [119]. In a retrospective
review of 697 intracranial metastases at Rush University
Medical Center, only 2.29% of these lesions directly or
indirectly (by secondary growth) involved the hippocampus
[121]. In “oligometastatic” patients (those with 1–3 metas-
tases only), the rate was even lower at 0.97% [121]. Because
hippocampal involvement by metastatic disease is rare, and
because memory loss (speciﬁcally the inability to consolidate
new memories) is such a frequent and major component
of late neurotoxicity from cranial irradiation, sparing of
the hippocampus during the administration of WBRT or
PCI should result in lower rates of memory loss [10–13,
15, 34, 63, 64, 73, 78, 119, 121] without compromise of
therapeutic goal. This is particularly supported by data from
St. Jude Children’s Hospital, who found that the primary
neurocognitive deﬁcit noted in children exposed to cranial
irradiation was the inability to form new memories, and
that loss of IQ after cranial irradiation correlated with the
dose delivered to the temporal lobes (the location of the
hippocampi) [15, 34].
Investigators at the University of Wisconsin have shown
that it is possible to selectively reduce dose to the hip-
pocampus (maximum dose constraint 6Gy) while treating
the whole brain to a D95 of 32.25Gy and treating metastatic
lesions to much higher doses (D95 of 63Gy for tumors
2cm + in max. diameter, and 70.8Gy for tumors <2cm
in max. diameter) [120]. Such signiﬁcant dose reductions
may be necessary to spare this structure, because the
hippocampus is known to be very sensitive to radiation
exposure, particularly the CA1 and subgranular zone (SGZ)
regions [125–128]. Apoptosis has been shown to peak at 12
hours after RT in the SGZ, and by 48 hours postirradiation,
the number of proliferating cells in the SGZ was reduced
by 93–96% [128]. This data suggests that impairment of
neurogenesis within the hippocampus, speciﬁcally within
the SGZ/dentate gyrus, may be at least partly responsible
for the cognitive impairments seen after brain irradiation
[127].
At our own institution, we have completed a dosimetric
feasibility study using helical tomotherapy (TomoTherapy,
Madison, WI) to restrict dose to the hippocampus and the
rest of the limbic circuit while simultaneously treating the
rest of the brain to full dose using treatment schedules for
both PCI and WBRT (30Gy in 15 fractions and 35Gy in 14
fractions, resp.) [129] .W ef o u n dt h a tw ew e r ea b l et or e d u c e
the mean dose to the hippocampus to 11.7Gy and 14Gy
in the PCI and WBRT plans, respectively; this constitutes a
mean relative reduction in BEDGy2 of 72.9% and 73.4% in
the PCI and WBRT plans, assuming an alpha/beta ratio of 2
for late brain adverse eﬀects [129].
Investigators in Vancouver have recently published the
results of a hippocampal sparing feasibility study in which
they successfully treated the whole brain to full dose
(32.25Gy) while simultaneously treating the bilateral hip-
pocampi to a mean dose of less than 6Gy and boosting
the metastatic lesions to 63–70.8Gy depending on diameter,
using volumetric modulated arc therapy (VMAT) [130].
Their mean treatment time was only 3.6 minutes [130].
Reduction of radiation exposure of the hippocampus
appears to be conceptually safe and dosimetrically feasible
and represents one of the most promising strategies for
maintaining the eﬃcacy of WBRT and PCI, while minimiz-
ing the morbidity previously described.8 Journal of Oncology
7.Sparingofthe Limbic Circuit
While dosimetric sparing of the hippocampus may reduce
the loss of memory consolidation noted after cranial radio-
therapy, selective sparing of the hippocampal formation
(dentate gyrus and cornu ammonis) may not be suﬃcient.
The hippocampal formation is only one of a number of
structures which constitute the limbic circuit, or circuit
of Papez [123]. The limbic circuit (Figures 1, 2,a n d3)
consists of 2 adjacent arches within the brain which bound
the ventricular system [123]. The inner arch (amygdala,
hippocampus [cornu ammonis and dentate gyrus], fornix,
and mammillary bodies) is separated from the outer arch
(parahippocampal gyrus, cingulum, cingulate gyrus, indu-
seum griseum, and paraterminal gyrus) by the hippocampal
sulcus and corpus callosum [123].
This circuit is critical to a number of vital brain
functions: integration and consolidation of new memo-
ries, special orientation, emotional responses and behavior,
autonomic responses to external stimuli, and ﬁne motor
coordination (among others) [123]. The two structures
most intimately associated with the hippocampus include
the parahippocampal gyrus and amygdaloid complex [123].
The parahippocampal gyrus is critical to memory encoding
and retrieval of memories, and its ventral-most portion,
called the entorhinal cortex, is the major source of aﬀer-
ent signals to the hippocampus [123]. The amygdaloid
complex, or amygdala, is involved in memory modulation
(required for long-term memory consolidation and the
association of memory with emotional and physiological
states) and emotional learning (fear reactions, imprinting,
breeding behaviors, etc.) [123]. These three structures—
the hippocampal formation, parahippocampal gyrus, and
amygdaloid complex—form a functional unit within the
medial temporal lobe, and true memory consolidation and
learning require the function of all three structures [123].
Otherstructuresthatconstitutethelimbiccircuitinclude
the cingulate gyrus (which regulates autonomic responses to
various stimuli and is involved in attention/concentration),
cingulum (white matter bundle adjacent to the cingulate
gyrus which connects the cingulated gyrus and prefrontal
area to the parahippocampal gyrus), fornix and mammillary
bodies (discussed previously) [123]. This circuit is directly
connected to, and modulates the function of, a number of
other critical intracranial structures including the hypotha-
lamus, thalamus, prefrontal and orbitofrontal cortices, and
nucleusaccumbens(thebrain’s“pleasurecenter”)[123].The
function of the circuit as a whole is to process memory,
support learning (cognitive, emotional, and autonomic),
regulate emotional states, and assist in spatial orientation
[123]. Interestingly, these are the most commonly reported
neurocognitive deﬁcits seen as components of late toxicity
from cranial irradiation [10]. This suggests that it is damage
tothiscriticalcircuitwhichisresponsibleformanyofthelate
sequelae of therapy. Thus, dosimetric sparing of the limbic
circuit may reduce such sequelae.
At our institution, we have performed a retrospective
review of 697 intracranial metastases in 107 patients. Limbic
metastases accounted for only 5.2% of all lesions. Among
patients with oligometastatic disease (1–3 metastases), the
rate was even lower at 4.8% [121] .T h er a t eo fh i p p o c a m p a l
formation involvement was less than 1% among oligo-
metastatic patients, while 3.9% of lesions involved the rest
of the limbic circuit [121].
In a subsequent dosimetric feasibility study conducted in
our department, we found that it was possible to restrict the
mean dose to the limbic circuit to 15.1Gy and 17.7Gy in PCI
(30Gy in 15 fractions) and WBRT (35Gy in 14 fractions)
plans, respectively, using helical TomoTherapy [129]. This
constitutes a mean reduction in BEDGy2 of 62.2% and
63.3% for the PCI and WBRT plans, respectively, assuming
an alpha/beta ratio of 2 for late brain side eﬀects [129]. The
mean doses and reductions in BEDGy2 for the hippocampal
formation (which was contoured separately) were even more
pronounced, as discussed previously [129].
Reduction of radiation exposure for the limbic circuit
may be safe, is dosimetrically feasible, and should reasonably
be expected to reduce rates of memory loss in patients
treated with cranial radiation therapy. These beneﬁts may
expand upon those obtained by dosimetric sparing of the
hippocampal formation alone.
8.Neural StemCellSparing
It is now known that the human brain contains regions of
mitotically active cells which retain the ability to divide and
diﬀerentiate along either neural or glial cell lines throughout
life [124]. These stems, known as neural stem cells (NSC,
Figure 4), are located in two speciﬁc areas of the brain: the
subgranularzone(SGZ)withinthedentategyrus(partofthe
hippocampus) and the subventricular zone (SVZ) adjacent
to the lateral aspect of the temporal horn and the occipital
trigone region of the lateral ventricles [131, 132]. These
cells are capable of increasing their mitotic rate under the
inﬂuence of appropriate stimuli (e.g., brain trauma, stroke,
radiation exposure, etc.) and can migrate through the brain
to damaged areas and repopulate areas of cortical neuronal
loss or white matter damage [133, 134]. They are also
involved in replacing the neurons that are lost as a result of
neurodegenerative disorders, and are important in learning
[135–142].
Itishypothesizedthatthelossofthesevitalcellsresultsin
the inability to repair radiation-induced damage to normal
brain tissue, the phenotypic expression of which is manifest
as memory loss, loss of executive function, and the other
late sequelae of therapy [144]. Preservation of the NSC
compartments during the administration of WBRT or PCI
should result in maintenance of the ability of the brain to
repair the damage generated by cranial irradiation and help
preserve neurocognitive function.
Barani et al. have shown that it possible to identify and
dosimetrically reduce dose to these regions using intensity-
modulatedradiationtherapy(IMRT)whiletreatingapatient
using treatment schedules applicable to whole brain radio-
therapy and a primary high-grade glioma [143]. They
selected a patient with a right paraventricular tumor and
prepared two IMRT treatment plans for the patient; the ﬁrstJournal of Oncology 9
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Figure 1: Hippocampus and Limbic Circuit (http://www.thebrain.mcgill.ca/).
Figure 2: Axial 3D rendering of the hippocampus (purple) and
limbic circuit (yellow) contours.
plan assumed that this mass represented a high-grade glioma
and treated the patient to 60Gy in 30 fractions, while the
second plan assumed that this mass was a metastatic lesion
and treated the patient with WBRT to 37.5Gy in 15 fractions
f o l l o w e db yas t e r e o t a c t i cr a d i o s u r g e r y( S R S )b o o s to f1 8G y .
They were able to reduce the dose to the NSC compartment
by 65% in the WBRT plan and 25% in the high-grade glioma
plan, even in this patient with a tumor with an unfavorable
location (adjacent to the right SVZ) [143].
Sparing of the NSC may be the single most eﬀective
method of mitigating the negative eﬀects of WBRT if these
cellssurviveandareabletorepairradiation-induceddamage.
The critical role of radiation-induced damage to the NSC
compartment as a cause of the cognitive dysfunction seen
after cranial irradiationhas had been recently reviewed, and
a considerable amount of evidence is available from in vitro
and animal studies which exists in support of this hypothesis
[145–151]. There is now also evidence from human studies
of patients treated with radiotherapy for malignant brain
tumors that cranial irradiation reduces the number of viable
NSC [152].
Investigators at our institution have completed a dosi-
metric feasibility study in which patients are treated with
either PCI (30Gy in 15 fractions) or WBRT (35Gy in 14
fractions) to full dose with simultaneous dosimetric sparing
of the hippocampal formation (including the SGZ) and
(a)
(b)
Figure 3: MRI images demonstrating location of (a) hippocampus,
and (b) fornix and cingulate gyrus (Marsh et al. [121]). (a) Hip-
pocampuscontouredoncoronal,sagittal,andaxialMRIimages.(b)
Axial MRI demonstrating location of fornix and cingulated gyrus
(anterior and posterior).
NSC compartment (SVZ, a 5mm expansion around the
lateral ventricle) [153]. The hippocampus and the rest of
the NSC compartment received a mean dose of 11.5Gy
in the PCI plans and 11.8Gy in the WBRT plans; this
constitutes a 65.8% reduction in BEDGy10 for the NSC
compartment in the PCI plans and a 70.8% reduction in the
WBRT plans (assuming an α/β r a t i oo f1 0f o rt h eN S Ci n
the SGZ and SVZ) [153]. The corresponding reductions in
BEDGy2 for the non-NSC component of the hippocampal10 Journal of Oncology
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Figure 4: Neural stem cell (NSC) regions of the brain (Barani et al.
[143]).
formation were 73.8% and 78.6% in the PCI and WBRT
plans, respectively (assuming an α/β ratio of 2 for the non-
NSC/diﬀerentiated portion of the hippocampal formation)
[153]. All NSC-preserving plans were generated using helical
TomoTherapy [153]. Thus, dosimetric sparing of the NSC
compartment has been proven feasible, and we believe
that pilot studies employing NSC sparing IMRT would be
appropriate.
9. Conclusions
While WBRT and PCI remain eﬀective therapies for the
treatment of, and prophylaxis against the development
of, intracranial metastases, they are associated with both
acute and late adverse eﬀects. These adverse eﬀects have
spurred interest in either eliminating or reducing the use
of these modalities or ﬁnding ways to reduce the incidence
of adverse sequalae. The hippocampus and limbic circuit
are also promising avoidance structures, as many of the
established late adverse eﬀects of both WBRT and PCI are
neurocognitive deﬁcits which result from damage to these
structures. There is currently interest at a number of centers
in selectively sparing these sensitive regions, while treating
the remainder of the at risk brain to an eﬀective dose. In the
setting of WBRT for brain metastases, and in the setting of
PCI, recent data suggests that sparing of these critical regions
may not compromise intracranial control. A novel potential
approach to reducing the late sequelae of cranial irradiation
is selective dosimetric avoidance of the brain’s neural stem
cell (NSC) compartment, which would help maintain the
brain’s natural ability to repair damage created by radiation
exposure.
Clinical trials utilizing selective sparing of critical brain
regions which prospectively incorporate neurocognitive test-
ing are justiﬁed and may potentially lead to the modern-
ization of a classical technique in radiation oncology. These
trials will likely employ one or another form of intensity-
modulated radiation therapy (IMRT), a technique which
allows for steep dose gradients to be generated around
even irregular or concave targets, as suggested by Movsas
at the November 2009 ASTRO presentation of RTOG 0214
[24]. The dosimetric feasibility study by Guti´ errez et al.
and Marsh et al. employed helical TomoTherapy, while
Barani et al. utilized traditional inverse-planned IMRT
[120, 129, 143, 153]. Investigators at our institution have
recently opened a Phase II trial in which patients with
limitedstageSCLC(whodemonstrateacompleteresponseto
treatment of their primary disease) and single resected brain
metastases (with no evidence of metastatic disease outside
the CNS) will be treated with limbic circuit-sparing PCI
(30Gy in 15 fractions) or WBRT (37.5Gy in 15 fractions)
using helical TomoTherapy [154]. Baseline and follow-up
cognitive function will be assessed with a formal battery
of neurocognitive tests, and results will be compared with
historical controls. Interim safety data will be reported to
documentanyfailureswithinthesparedregionsofthebrain.
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